Aldose reductase is a member of the aldo-keto reductase enzyme family that is present in mammalian tissues. It is a monomeric NADPH-binding protein that catalyzes the reduction of aldoses to their corresponding sugar alcohols. Using NADPH as coenzyme, aldose reductase catalyzes the initial reaction of the sorbitol pathway, also called the polyol pathway.1–3 Oxidation of sorbitol to fructose, catalyzed by the enzyme sorbitol dehydrogenase, which uses the cofactor NAD as the electron acceptor, constitutes the second reaction in this pathway, according to the scheme depicted in Figure 2-1.


Aldose Reductase Aldose Reductase Inhibitor Sorbitol Dehydrogenase Aldehyde Reductase Bovine Lens 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hers HG: Le mécanisme de la transformation de glucose en fructose par les vesicules séminales. Biochim Biophys Acta 1956; 22:202–203.PubMedCrossRefGoogle Scholar
  2. 2.
    Hayman S, Kinoshita JH: Isolation and properties of lens aldose reductase. J Biol Chem 1965; 240:877–882.PubMedGoogle Scholar
  3. 3.
    Gabbay KH: The sorbitol pathway and complications of diabetes. N Engl J Med 1973; 288:831–836.PubMedCrossRefGoogle Scholar
  4. 4.
    Cogan DG, Kinoshita JH, Kador PF, et al: Aldose reductase and complications of diabetes. Ann Intern Med 1984; 101:82–91.PubMedGoogle Scholar
  5. 5.
    Kinoshita JH, Futterman S, Satoh K, et al: Factors affecting the formation of sugar alcohols in ocular lens. Biochim Biophys Acta 1963; 74:340–350.PubMedCrossRefGoogle Scholar
  6. 6.
    Chylack LT, Kinoshita JH: A biochemical evaluation of a cataract induced in a high glucose medium. Invest Ophthalmol 1969; 8:401–412.PubMedGoogle Scholar
  7. 7.
    LeFevre PG, Davies RI: Active transport into the human erythrocyte: Evidence from comparative kinetics and competition among monosaccharides. J Gen Physiol 1951; 34:515–524.PubMedCrossRefGoogle Scholar
  8. 8.
    Wick AN, Drury DR: Action of insulin on the permeability of cells to sorbitol. Am J Physiol 1951; 166:421–423.PubMedGoogle Scholar
  9. 9.
    Kinoshita JH: Cataracts in galactosemia. Invest Ophthalmol 1965; 4:786–799.PubMedGoogle Scholar
  10. 10.
    Hers HG: Le mécanisme de la formation du fructose séminal et du fructose foetal. Biochim Biophys Acta 1960; 37:127–138.PubMedCrossRefGoogle Scholar
  11. 11.
    Hastein T, Velle W: Placental aldose reductase activity and foetal blood fructose during bovine pregnancy. J Reprod Fertil 1968; 15:47–52.PubMedCrossRefGoogle Scholar
  12. 12.
    Hastein T, Velle W: Purification and properties of aldose reductase from the placental and seminal vesicle of the sheep. Biochim Biophys Acta 1969; 178:1–10.PubMedGoogle Scholar
  13. 13.
    Clements R, Winegrad AI: Purification of alditol NADP oxidoreductase from human placenta. Biochem Biophys Res Commun 1972; 47:1473–1480.PubMedCrossRefGoogle Scholar
  14. 14.
    Kador PF, Carper D, Kinoshita JH: Rapid purification of human placental aldose reductase. Anal Biochem 1981; 114:53–58.PubMedCrossRefGoogle Scholar
  15. 15.
    Hoffman PL, Wermuth B, von Wartburg J-P: Human brain aldehyde reductases: Relationship to succinic seminaldehyde reductase and aldose reductase. J Neurochem 1980; 35:354–366.PubMedCrossRefGoogle Scholar
  16. 16.
    Dons RF, Doughty CC: Isolation and characterization of aldose reductase from calf brain. Biochim Biophys Acta 1976; 452:1–12.PubMedGoogle Scholar
  17. 17.
    Boghosian RA, McGuiness ET: Affinity purification and properties of porcine brain aldose reductase. Biochim Biophys Acta 1979; 567:278–286.PubMedGoogle Scholar
  18. 18.
    Moonsammy GI, Stewart MA: Purification and properties of brain aldose reductase and l-hexonate dehydrogenase. J Neurochem 1967; 14:1187–1193.PubMedCrossRefGoogle Scholar
  19. 19.
    O’Brien MM, Schofield PJ: Polyol pathway enzymes of human brain. Biochem J 1980; 187:21–30.PubMedGoogle Scholar
  20. 20.
    Boghosian RA, McGuiness ET: Pig brain aldose reductase: A kinetic study using centrifugal fast analyzer. Int J Biochem 1981; 13:909–914.PubMedCrossRefGoogle Scholar
  21. 21.
    Wermuth B, Burgesser H, Bohren K, et al: Purification and characterization of human-brain aldose reductase. Eur J Biochem 1982; 127:279–284.PubMedCrossRefGoogle Scholar
  22. 22.
    Ris MM, von Wartburg J: Heterogeneity of NADPH-dependent aldehyde reductase from human and rat brain. Eur J Biochem 1973; 37:69–77.PubMedCrossRefGoogle Scholar
  23. 23.
    Turner AJ, Tipton KF: The characterization of two reduced nicotinamide-adenine dinucleotide phosphate-linked aldehyde reductases from pig brain. Biochem J 1972; 130:765–772.PubMedGoogle Scholar
  24. 24.
    Jedziniak JA, Chylack LT, Cheng H-M, et al: The sorbitol pathway in human lens: Aldose reductase and polyol dehydrogenase. Invest Ophthalmol Vis Sci 1981; 20:314–326.PubMedGoogle Scholar
  25. 25.
    Sheaf CM, Doughty CC: Physical and kinetic properties of homogeneous bovine lens. J Biol Chem 1976; 251:2696–2702.Google Scholar
  26. 26.
    Hay man S, Lou MF, Merola LO, et al: Aldose reductase activity in the lens and other tissues. Biochim Biophys Acta 1966; 128:474–482.Google Scholar
  27. 27.
    Branlant G: Properties of an aldose reductase from pig lens. Eur J Biochem 1982; 129:99–104.PubMedCrossRefGoogle Scholar
  28. 28.
    Crabbe MJC, Haider AB: Affinity chromatography of bovine lens aldose reductase, and a comparison of some kinetic properties of the enzyme from lens and human erythrocyte. Biochem Soc Trans 1980; 8:194–195.PubMedGoogle Scholar
  29. 29.
    Conrad SM, Doughty CC: Comparative studies on aldose reductase from bovine, rat and human lens. Biochim Biophys Acta 1982; 708:348–357.PubMedCrossRefGoogle Scholar
  30. 30.
    Hermann RK, Kador PF, Kinoshita JH: Rat lens aldose reductase: Rapid purification and comparison with human placental aldose reductase. Exp Eye Res 1983; 37:467–474.CrossRefGoogle Scholar
  31. 31.
    Inagaki K, Miwa I, Okuda J: Affinity purification and glucose specificity of aldose reductase in bovine lens. Arch Biochem Biophys 1979; 216:337–344.CrossRefGoogle Scholar
  32. 32.
    Tanimoto T, Fukuda H, Kawamura J: Purification and some properties of aldose reductase from rabbit lens. Chem Pharm Bull (Tokyo) 1983; 31:2395–2403.Google Scholar
  33. 33.
    Doughty CC, Lee S-M, Conrad S, et al: Kinetic mechanism and structural properties of lens aldose reductase, in Weiner H, Wermuth B (eds): Enzymology of Carbonyl Metabolism: Aldehyde Dehydrogenase and Aldo/Keto Reductase, pp 223–242. New York, Alan R. Liss, 1982.Google Scholar
  34. 34.
    Attwood MA, Doughty CC: Purification and properties of calf liver aldose reductase. Biochim Biophys Acta 1974; 370:358–368.PubMedGoogle Scholar
  35. 35.
    Haider AB, Wolff S, Ting H-H, et al: An aldose reductase from human erythrocyte. Biochem Soc Trans 1980; 8:644–645.Google Scholar
  36. 36.
    Das B, Srivastava SK: Purification and properties of aldose reductase and aldehyde reductase II from human erythrocyte. Arch Biochem Biophys 1985; 238:670–679.PubMedCrossRefGoogle Scholar
  37. 37.
    Cromlish JA, Flynn TG: Pig muscle aldehyde reductase. Identity of pig muscle aldehyde reductase with pig lens aldose reductase and with low Km aldehyde reductase of pig brain and pig kidney. J Biol Chem 1983; 258:3583–3586.PubMedGoogle Scholar
  38. 38.
    Cromlish JA, Flynn TG: Purification and characterization of two aldose reductase isoenzymes from rabbit muscle. J Biol Chem 1983; 256:3416–3424.Google Scholar
  39. 39.
    Gabbay KH, O’Sullivan JB: The sorbitol pathway in diabetes and galactosemia: Enzyme localization and changes in kidney. 1968; Diabetes 17:300.PubMedGoogle Scholar
  40. 40.
    Gabbay KH, Cathcart ES: Purification and immunologic identification of aldose reductases. Diabetes 1974; 23:460–468.PubMedGoogle Scholar
  41. 41.
    Morrison AD, Clements RS Jr, Winegrad AI: Effects of elevated glucose concentrations on the metabolism of the aortic wall. J Clin Invest 1972; 51:3114–3123.PubMedCrossRefGoogle Scholar
  42. 42.
    Srivastava SK, Ansari NH, Hair GA, et al: Aldose and aldehyde reductase in human tissues. Biochim Biophys Acta 1984; 800:220–227.PubMedGoogle Scholar
  43. 43.
    Wirth H-P, Wermuth B: Immunochemical characterization of aldo-keto reductases from human tissues. FEBS Lett 1985; 187:280–282.PubMedCrossRefGoogle Scholar
  44. 44.
    Kern TS, Engerman RL: Immunohistochemical distribution of aldose reductase. Histochem J 1982; 14:507–515.PubMedCrossRefGoogle Scholar
  45. 45.
    Ludvigson MA, Sorenson RL: Immunohistochemical localization of aldose reductase. I. Enzyme purification and antibody preparation—localization in peripheral nerve, artery and testis. Diabetes 1980; 29:438–449.PubMedCrossRefGoogle Scholar
  46. 46.
    Ludvigson MA, Sorenson RL: Immunohistochemical localization of aldose reductase. II. Rat eye and kidney. Diabetes 1980; 29:450–459.PubMedCrossRefGoogle Scholar
  47. 47.
    Sheys GH, Arnold WJ, Watson JA, et al: Aldose reductase from Rhodotorula. J Biol Chem 1971; 246:3824–3827.Google Scholar
  48. 48.
    Sheys GH, Doughty CC: The reaction mechanism of aldose reductase from Rhodotorula. Biochim Biophys Acta 1971; 242:523–531.Google Scholar
  49. 49.
    Goil MM, Harpur RP: Aldose reductase and sorbitol dehydrogenase in the muscle of Ascaris suum (Nematoda). Parasitology 1978; 77:97–102.PubMedCrossRefGoogle Scholar
  50. 50.
    Halder AB, Crabbe MJC: Bovine lens aldehyde reductase (aldose reductase). Purification, kinetics and mechanism. Biochem J 1984; 219:33–39.PubMedGoogle Scholar
  51. 51.
    Feldman HB, Szczepanik PA, Harne P: Stereospecificity of the hydrogen transfer catalyzed by human placental aldose reductase. Biochim Biophys Acta 1977; 480:14–20.PubMedGoogle Scholar
  52. 52.
    Crabbe MJC, Haider AB: Kinetic behavior under defined assay conditions for bovine lens aldose reductase. Clin Biochem 1979; 12:281–283.PubMedCrossRefGoogle Scholar
  53. 53.
    Markus HB, Raducha M, Harris H: Tissue distribution of mammalian aldose reductase and related enzymes. Biochem Med 1983; 29:31–45.PubMedCrossRefGoogle Scholar
  54. 54.
    Srivastava SK, Hair GA, Das B: Activated and unactivated forms of human erythrocyte aldose reductase. Proc Natl Acad Sci USA 1985; 82:7222–7226.PubMedCrossRefGoogle Scholar
  55. 55.
    Das B, Hair GA, Srivastava SK: Activated and unactivated forms of aldose reductase and its role in diabetic complications. Fed Proc 1985; 44:1391(A).Google Scholar
  56. 56.
    Das B, Srivastava SK: Activation of aldose reductase from tissues. Diabetes 1985; 34:1145–1151.PubMedCrossRefGoogle Scholar
  57. 57.
    Jedziniak JA, Kinoshita JH: Activators and inhibitors of lens aldose reductase. Invest Ophthalmol 1971; 10:357–366.PubMedGoogle Scholar
  58. 58.
    Kinoshita JH, Dvornik D, Kraml M, et al: The effect of an aldose reductase inhibitor on the galactose-exposed rabbit lens. Biochim Biophys Acta 1968; 158:472–475.PubMedGoogle Scholar
  59. 59.
    Kinoshita JH, Fukushi S, Kador P, et al: Aldose reductase in diabetic complications of the eye. Metabolism 1979; 28(suppl I):462–469.PubMedCrossRefGoogle Scholar
  60. 60.
    Hutton JC, Williams JF, Schofield PJ, et al: Polyol metabolism in monkey-kidney epithelial-cell cultures. Eur J Biochem 1974; 49:347–353.PubMedCrossRefGoogle Scholar
  61. 61.
    Obazawa H, Merola LO, Kinoshita JH: The effects of xylose on the isolated lens. Invest Ophthalmol Vis Sci 1974; 13:204–209.Google Scholar
  62. 62.
    Hutton JC, Schofield PJ, Williams JF, et al: The failure of aldose reductase inhibitor 3,3′-tetramethylene glutaric acid to inhibit in vivo sorbitol accumulation in lens and retina in diabetes. Biochem Pharmacol 1974; 23:2991–2998.PubMedCrossRefGoogle Scholar
  63. 63.
    Gabbay KH, Kinoshita JH: Growth hormone sorbitol, and diabetic capillary disease. Lancet 1971; 1:913.PubMedCrossRefGoogle Scholar
  64. 64.
    Chylack LT Jr, Henriques HF, Cheng H-M, et al: Efficacy of alrestatin, an aldose reductase inhibitor, in human diabetic and nondiabetic lenses. Ophthalmology 1979; 86:1579.PubMedGoogle Scholar
  65. 65.
    Varma SD, Mukuni I, Kinoshita JH: Flavinoids as inhibitors of lens aldose reductase. Science 1975; 188:1215–1216.PubMedCrossRefGoogle Scholar
  66. 66.
    Dvornik D, Simard-Duquesne N, Kraml M, et al: Polyol accumulation in galactosemic and diabetic rats: Control by an aldose reductase inhibitor. Science 1973; 182:1146–1148.PubMedCrossRefGoogle Scholar
  67. 67.
    Okuda J, Miwa I, Inagaki K, et al: Inhibition of aldose reductases from rat and bovine lenses by flavinoids. Biochem Pharmacol 1982; 31:3807–3822.PubMedCrossRefGoogle Scholar
  68. 68.
    Segelman AB, Segelman FP, Varma SD, et al:Cannabis sativa L. (Marijuana) IX: Lens aldose reductase inhibitory activity of marijuana flavone C-glycosides. J Pharm Sci 1977; 66:1358–1359.PubMedCrossRefGoogle Scholar
  69. 69.
    Beyer-Mears A, Farnsworth PN: Diminished diabetic catactogenesis by quercitin. Exp Eye Res 1979; 28:709–716.PubMedCrossRefGoogle Scholar
  70. 70.
    Peterson MJ, Sarges R, Aldinger CE, et al: CP-45,634: A novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats. Metabolism 1979; 28(suppl 1):456–461.PubMedCrossRefGoogle Scholar
  71. 71.
    Fukushi H, Merola L, Kinoshita J: Altering the course of cataracts in diabetic rats. Invest Opthalmol Vis Sci 1980; 19:313–315.Google Scholar
  72. 72.
    Poulson R, Boot-Hanford RP, Heath H: Some effects of aldose reductase inhibition upon the eyes of long-term streptozotocin-diabetic rats. Curr Eye Res 1982; 2:351–355.CrossRefGoogle Scholar
  73. 73.
    Jacobson MJ, Sharma RJ, Cotlier E, et al: Diabetic complications in lens and nerve and their prevention by sulindac or Sorbinil: Two novel aldose reductase inhibitors. Invest Ophthalmol Vis Sci 1983; 24:1426–1429.PubMedGoogle Scholar
  74. 74.
    Richon AB, Maragoudakis ME, Wasvary JS: Isoxazolidine-3,5-diones as lens aldose reductase inhibitors. J Med Chem 1982; 25:745–747.PubMedCrossRefGoogle Scholar
  75. 75.
    Sohda T, Mizuno K, Imamiya E, et al: Studies on antidiabetic agents. 5-Arylthiazolidine-2,4-diones as potent aldose reductase inhibitors. Chem Pharm Bull 1982; 30:3601–3616.PubMedGoogle Scholar
  76. 76.
    Schnur RC, Sarges R, Peterson MJ: Spiro oxazolidinedione aldose reductase inhibitors. J Med Chem 1982; 25:1451–1454.PubMedCrossRefGoogle Scholar
  77. 77.
    Pfister JR, Wymann WE, Mahoney JM, et al: Synthesis and aldose reductase inhibitor activity of 7-sulfamoylxanthone-2-carboxylic acids. J Med Chem 1980; 23:1264–1267.PubMedCrossRefGoogle Scholar
  78. 78.
    Kador PF, Sharp less NE: Structure-activity studies of aldose reductase inhibitors containing the 4-oxo-4H-chromen ring system. Biophys Chem 1978; 8:81–85.PubMedCrossRefGoogle Scholar
  79. 79.
    Simard-Duquesne N, Greslin E, Dubuc J, et al: The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats. Metabolism 1985; 34:885–892.PubMedCrossRefGoogle Scholar
  80. 80.
    Sestanj K, Bellini F, Fung S, et al: N([5-(trifluoromethyl)-6-methoxy-l-naph-thalenyl]thioxomethyl)-N-methylglycine (tolrestat), a potent orally active aldose reductase inhibitor. J Med Chem 1984; 27:255–256.PubMedCrossRefGoogle Scholar
  81. 81.
    Inagaki K, Miwa I, Yashiro T, et al: Inhibition of aldose reductases from rat and bovine lenses by hydantoin derivatives. Chem Pharmacol Bull 1984; 30:3244–3254.Google Scholar
  82. 82.
    Chaudhry PS, Cabrera J, Juliani HR, et al: Inhibition of human lens aldose reductase by flavinoids, sulindac and indomethacin. Biochem Pharmacol 1983; 32:1995–1998.PubMedCrossRefGoogle Scholar
  83. 83.
    Crabbe MJC, Freeman G, Haider AB, et al: The inhibition of bovine lens aldose reductase by Clinoril, its absorption into the human red cell and its effect on human red cell aldose reductase activity. Ophthalmic Res 1985; 17:85–89.PubMedCrossRefGoogle Scholar
  84. 84.
    Kikkawa R, Hatanaka I, Yasuda H, et al: Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5[(2E)-methyl-3-phenylpropenylidene] rhodanine (ONO-2235), on peripheral nerve disorders in streptozotocin-diabetic rats. Diabetologia 1984; 24:290–292.Google Scholar
  85. 85.
    Sharma YR, Cotlier E: Inhibition of lens and cataract aldose reductase by protein bound anti-rheumatic drugs: Salicylate, indomethacin, oxyphenbutazone, sulindac. Exp Eye Res 1982; 35:21–27.PubMedCrossRefGoogle Scholar
  86. 86.
    Kador PF, Sharpless NE, Goosey JD: Aldose reductase inhibition by antiallergy compounds, in Weiner H, Wermuth B (eds): Enzymology of Carbonyl Metabolism: Aldehyde Dehydrogenase and Aldo/Keto Reductase, pp 243–259. New York, Alan R. Liss, 1982.Google Scholar
  87. 87.
    Ono H, Hayano S : 2,2′,4′4′-Tetrahydroxybenzophenone as a new aldose reductase inhibitor. Nippon Ganka Gakkai Zasshi 1982; 86:353–357.PubMedGoogle Scholar
  88. 88.
    Kador PF, Goosey JD, Sharpless NE, et al: Stereospecific inhibition of aldose reductase. Eur J Med Chem 1981; 16:293–298.Google Scholar
  89. 89.
    Varma SD, Kinoshita JH: Inhibition of lens aldose reductase by flavinoids. Biochem Pharmacol 1976; 25:2505–2513.PubMedCrossRefGoogle Scholar
  90. 90.
    Kador PF, Sharpless NE: Pharmacophor requirements of the aldose reductase inhibitor site. Mol Pharmacol 1983; 24:521–531.PubMedGoogle Scholar
  91. 91.
    Haider AB, Crabbe MJCC: Inhibition of aldose reductase by phenylglyoxal, diethylpyrocarbonate and thiol modifiers. Biochem Soc Trans 1982; 10: 401–403.Google Scholar
  92. 92.
    Wolff SPV Crabbe MJC, Thornally PJ: Autoxidation of glyceraldehyde and other simple monosaccharides. Experientia 1984; 40:244–246.CrossRefGoogle Scholar
  93. 93.
    Thornally PJ, Wolff SP, Crabbe MJC, et at: Autoxidation of glyceraldehyde and other monosaccharides catalyzed by buffer ions. Biochim Biophys Acta 1984; 797:276–287.Google Scholar
  94. 94.
    O’Brien MM, Schofield PJ, Edwards MR: Inhibition of human brain aldose reductase and hexonate dehydrogenase by alrestatin and Sorbinil. J Neurochem 1982; 39:810–814.PubMedCrossRefGoogle Scholar
  95. 95.
    Srivastava SK, Petrash JM, Sadana IJ, et al: Susceptibility of aldehyde and aldose reductase of human tissues to aldose reductase inhibitors. Curr Eye Res 1982; 2:407–410.PubMedCrossRefGoogle Scholar
  96. 96.
    Kador PL, Merola LQ, Kinoshita JH: Differences in the susceptibility of aldose reductase to inhibition. Doc Ophthalmol Proc Ser 1979; 18:117–124.Google Scholar
  97. 97.
    Kador PF, Kinoshita JH, Tung WH, et al: Differences in the susceptibility of aldose reductase to inhibition. Invest Ophthalmol Vis Sci 1980; 19:980–982.PubMedGoogle Scholar
  98. 98.
    Yoshida H: The characteristics of aldose reductase in human lens, placenta, and rat organs. Nippon Ganka Gakkai Zasshi 1981; 85:865–869.PubMedGoogle Scholar
  99. 99.
    Maragoudakis ME, Wasvary J, Gaigiulo P, et al: Human placental aldose reductase: Sensitive and insensitive forms to inhibition by alrestatin. Fed Proc 1979; 30:255(A).Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1987

Authors and Affiliations

  • Margo Panush Cohen
    • 1
  1. 1.Division of Endocrinology and MetabolismUniversity of Medicine and Dentistry of New JerseyNewarkUSA

Personalised recommendations